Delving into the Latest Updates on SXR-1096 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target

Mechanism

KLK14 inhibitors(kallikrein related peptidase 14 inhibitors), KLK5 inhibitors(kallikrein related peptidase 5 inhibitors), KLK7 inhibitors(kallikrein related peptidase 7 inhibitors)

Therapeutic Areas

Congenital DisordersSkin and Musculoskeletal DiseasesOther Diseases

Active Indication-

Inactive Indication

Netherton Syndrome

Originator Organization

Sixera Pharma ABStartup

Active Organization-

Inactive Organization

Sixera Pharma ABStartup

Drug Highest PhasePendingPhase 1/2

First Approval Date-

Regulation-

Login to view timeline

In this phase I/II trial a topical skin cream with the active substance SXR1096 will be tested in patients with Netherton syndroms, a rare inflammatory skin disease. SXR1096 is a specific and potent protease inhibitor that can inhibit the proteases kallikrein 5, 7 and 14 - all recognised as up-regulated and causing the disease state in Netherton syndrome patients. Patients will be treated for one month with active cream and placebo cream at different areas of the skin.

Start Date07 Dec 2021

Sponsor / Collaborator

Sixera Pharma ABStartup

100 Clinical Results associated with SXR-1096

Login to view more data

100 Translational Medicine associated with SXR-1096

Login to view more data

100 Patents (Medical) associated with SXR-1096

Login to view more data

100 Deals associated with SXR-1096

Login to view more data